405 related articles for article (PubMed ID: 21510839)
21. 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
Tsu H; Chen X; Chen CT; Lee SJ; Chang CN; Kao KH; Coumar MS; Yeh YT; Chien CH; Wang HS; Lin KT; Chang YY; Wu SH; Chen YS; Lu IL; Wu SY; Tsai TY; Chen WC; Hsieh HP; Chao YS; Jiaang WT
J Med Chem; 2006 Jan; 49(1):373-80. PubMed ID: 16392822
[TBL] [Abstract][Full Text] [Related]
22. Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer.
Kotacková L; Baláziová E; Sedo A
Folia Biol (Praha); 2009; 55(3):77-84. PubMed ID: 19545486
[TBL] [Abstract][Full Text] [Related]
23. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.
Kim NH; Yu T; Lee DH
Biomed Res Int; 2014; 2014():368703. PubMed ID: 25140306
[TBL] [Abstract][Full Text] [Related]
24. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
[TBL] [Abstract][Full Text] [Related]
25. 4-Substituted boro-proline dipeptides: synthesis, characterization, and dipeptidyl peptidase IV, 8, and 9 activities.
Wu W; Liu Y; Milo LJ; Shu Y; Zhao P; Li Y; Woznica I; Yu G; Sanford DG; Zhou Y; Poplawski SE; Connolly BA; Sudmeier JL; Bachovchin WW; Lai JH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5536-40. PubMed ID: 22853995
[TBL] [Abstract][Full Text] [Related]
26. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
27. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.
Demuth HU; McIntosh CH; Pederson RA
Biochim Biophys Acta; 2005 Aug; 1751(1):33-44. PubMed ID: 15978877
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst JJ; Deacon CF
Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
[TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
30. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
32. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.
Rosenblum JS; Kozarich JW
Curr Opin Chem Biol; 2003 Aug; 7(4):496-504. PubMed ID: 12941425
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases.
Augustyns K; Van der Veken P; Senten K; Haemers A
Curr Med Chem; 2005; 12(8):971-98. PubMed ID: 15853709
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
35. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors.
Lu IL; Lee SJ; Tsu H; Wu SY; Kao KH; Chien CH; Chang YY; Chen YS; Cheng JH; Chang CN; Chen TW; Chang SP; Chen X; Jiaang WT
Bioorg Med Chem Lett; 2005 Jul; 15(13):3271-5. PubMed ID: 15927466
[TBL] [Abstract][Full Text] [Related]
36. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.
Connolly BA; Sanford DG; Chiluwal AK; Healey SE; Peters DE; Dimare MT; Wu W; Liu Y; Maw H; Zhou Y; Li Y; Jin Z; Sudmeier JL; Lai JH; Bachovchin WW
J Med Chem; 2008 Oct; 51(19):6005-13. PubMed ID: 18783201
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.
Mentlein R
Expert Opin Investig Drugs; 2005 Jan; 14(1):57-64. PubMed ID: 15709922
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation.
Han R; Wang X; Bachovchin W; Zukowska Z; Osborn JW
Sci Rep; 2015 Aug; 5():12348. PubMed ID: 26242871
[TBL] [Abstract][Full Text] [Related]
39. [The incretin effect: a new therapeutic target in type 2 diabetes].
Féry F
Rev Med Brux; 2007 Sep; 28(4):329-35. PubMed ID: 17958029
[TBL] [Abstract][Full Text] [Related]
40. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
